Special Issue "Novel Therapeutics and Prognostications in Gastrointestinal Cancer"
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 6560
Interests: urothelial cancer; sarcoma; molecular pathology; experimental therapeutics
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: The Utility and Relevance of Comprehensive Genomic Profiling in Cancer
Special Issue in International Journal of Molecular Sciences: Molecular Pathogenesis and Therapeutics in Urothelial Carcinoma
Special Issue in Life: Novel Therapeutics and Prognostications in Gastrointestinal Cancers
Gastrointestinal (GI) cancer is one of the most common cancers worldwide and leads to a number of cancer-related cases of morbidity and mortality. GI cancer is heterogeneous, involving a wide range of organs including the esophagus, stomach, hepatobiliary system, pancreas, small and large intestines, rectum, and anus. It is also quite diverse as regards its histological types, which consist mainly of adenocarcinoma, followed by neuroendocrine tumor, sarcoma, and hematopoietic neoplasms. The etiology is also quite diverse. For example, gastroesophageal reflux disease, Helicobacter pylori, inflammatory bowel disease, and hepatitis B or C virus infection are associated with the development of esophageal, gastric, intestinal, and liver cancers, respectively. Of note, a certain number of GI cancers can be inherited. It is also worth noting that GI cancer is often diagnosed in an advanced stage. For those, traditional chemotherapy may benefit patient outcome, but survival remains poor. Recently, various targeted therapies have been developed based on an increased understanding of the molecular features and immunogenicity of GI cancers, and remarkable survival benefits in certain subsets of patients have been archived. Accordingly, systemic identification and validation of novel therapeutics and prognostic models and biomarkers would most likely be beneficial for patients.
With this concept, the aim of this Special Issue is to collect manuscripts associated with the following points to allow the delivery of precision oncology in GI cancers:
- Prognostic patterns/models (either statistics or biomedical) for GI cancers;
- Novel biomarkers carrying either therapeutic or prognostic values for GI cancers;
- Novel agents or novel strategies for the treatment of GI cancers, either in vitro or in vivo.
Prof. Dr. Chien-Feng Li
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Gastroenterology Insights is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- gastrointestinal cancers